These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

97 related articles for article (PubMed ID: 1848064)

  • 1. Neutralization activity of some Coxsackie B3 antibodies is compromised by protein factor(s) secreted by Vero cells.
    Konishi K; Kawabata M; Ohtaki K
    Arch Virol; 1991; 116(1-4):197-207. PubMed ID: 1848064
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Neutralization Assay for Chikungunya Virus Infection: Plaque Reduction Neutralization Test.
    Azami NA; Moi ML; Takasaki T
    Methods Mol Biol; 2016; 1426():273-82. PubMed ID: 27233280
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Neutralizing antibodies to Coxsackie virus group B 1986-1988].
    Kuljić-Kapulica N; Zivanović-Marinković V; Krstić L; Nozić M; Budisin A
    Vojnosanit Pregl; 1990; 47(4):294-6. PubMed ID: 2173272
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Improving ability of RSV microneutralization assay to detect G-specific and cross-reactive neutralizing antibodies through immortalized cell line selection.
    Boukhvalova MS; Mbaye A; Kovtun S; Yim KC; Konstantinova T; Getachew T; Khurana S; Falsey AR; Blanco JCG
    Vaccine; 2018 Jul; 36(31):4657-4662. PubMed ID: 29960801
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Susceptibility of the VERO line of African green monkey kidney cells to human enteroviruses.
    Davis PM; Phillpotts RJ
    J Hyg (Lond); 1974 Feb; 72(1):23-30. PubMed ID: 4361500
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Dengue 1 virus binding to human hepatoma HepG2 and simian Vero cell surfaces differs.
    Marianneau P; Mégret F; Olivier R; Morens DM; Deubel V
    J Gen Virol; 1996 Oct; 77 ( Pt 10)():2547-54. PubMed ID: 8887489
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The synergistic neutralization of Rift Valley fever virus by monoclonal antibodies to the envelope glycoproteins.
    Besselaar TG; Blackburn NK
    Arch Virol; 1992; 125(1-4):239-50. PubMed ID: 1642552
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Evidence against an important role for infectivity-enhancing antibodies in Ebola virus infections.
    Geisbert TW; Hensley LE; Geisbert JB; Jahrling PB
    Virology; 2002 Feb; 293(1):15-9. PubMed ID: 11853394
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Generation of murine monoclonal antibodies which cross-neutralize human enterovirus genogroup B isolates.
    Chang HW; Liu CC; Lin MH; Ho HM; Yang YT; Chow YH; Chong P; Sia C
    J Virol Methods; 2011 May; 173(2):189-95. PubMed ID: 21315763
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Neutralizing monoclonal antibody to the E1 glycoprotein epitope of rubella virus mediates virus arrest in VERO cells.
    Cordoba P; Grutadauria S; Cuffini C; Zapata M
    Viral Immunol; 2000; 13(1):83-92. PubMed ID: 10733171
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Avian reovirus proteins associated with neutralization of virus infectivity.
    Wickramasinghe R; Meanger J; Enriquez CE; Wilcox GE
    Virology; 1993 Jun; 194(2):688-96. PubMed ID: 8503182
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Passive immune protection by herpes simplex virus-specific monoclonal antibodies with different plaque development inhibition activity.
    Mannini-Palenzona A; Costanzo F; Cassai E; Campana G
    New Microbiol; 1993 Jul; 16(3):205-13. PubMed ID: 8396193
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Neutralization of antibody-enhanced dengue infection by VIS513, a pan serotype reactive monoclonal antibody targeting domain III of the dengue E protein.
    Budigi Y; Ong EZ; Robinson LN; Ong LC; Rowley KJ; Winnett A; Tan HC; Hobbie S; Shriver Z; Babcock GJ; Alonso S; Ooi EE
    PLoS Negl Trop Dis; 2018 Feb; 12(2):e0006209. PubMed ID: 29425203
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Neutralization of aggregated strains of enterovirus 71 and echovirus type 4 in RD and Vero or GMK-AH1 cells.
    von Zeipel G
    Acta Pathol Microbiol Scand B; 1979 Feb; 87B(1):71-3. PubMed ID: 219662
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Antigenic sites of coxsackie A9 virus inducing neutralizing monoclonal antibodies protective in mice.
    Buttinelli G; Donati V; Ruggeri FM; Joki-Korpela P; Hyypia T; Fiore L
    Virology; 2003 Jul; 312(1):74-83. PubMed ID: 12890622
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Optimization of microcarrier cell culture process for the inactivated enterovirus type 71 vaccine development.
    Wu SC; Liu CC; Lian WC
    Vaccine; 2004 Sep; 22(29-30):3858-64. PubMed ID: 15364432
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Evaluation of single-round infectious, chimeric dengue type 1 virus as an antigen for dengue functional antibody assays.
    Yamanaka A; Suzuki R; Konishi E
    Vaccine; 2014 Jul; 32(34):4289-95. PubMed ID: 24950360
    [TBL] [Abstract][Full Text] [Related]  

  • 18.
    van Erp EA; van Kasteren PB; Guichelaar T; Ahout IML; de Haan CAM; Luytjes W; Ferwerda G; Wicht O
    J Virol; 2017 Nov; 91(21):. PubMed ID: 28794038
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Estimation of focus reduction neutralization test for measurement of neutralizing antibody titer against Japanese encephalitis virus.
    Watanabe K; Hirokawa C; Kon M; Tamura T; Nishikawa M
    Jpn J Infect Dis; 2008 Sep; 61(5):424-5. PubMed ID: 18806361
    [No Abstract]   [Full Text] [Related]  

  • 20. Development of a micro-neutralization assay for ebolaviruses using a replication-competent vesicular stomatitis hybrid virus and a quantitative PCR readout.
    Lee SS; Phy K; Peden K; Sheng-Fowler L
    Vaccine; 2017 Oct; 35(41):5481-5486. PubMed ID: 28427845
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.